Cargando…

Prognostic role of a new inflammatory index with neutrophil-to-lymphocyte ratio and lactate dehydrogenase (CII: Colon Inflammatory Index) in patients with metastatic colorectal cancer: results from the randomized Italian Trial in Advanced Colorectal Cancer (ITACa) study

Aim: The aim of this study was to investigate the role of a new inflammatory index (Colon Inflammatory Index [CII]) as a predictor of prognosis and treatment efficacy in patients with metastatic colorectal cancer (mCRC) enrolled in the prospective multicenter randomized ITACa (Italian Trial in Advan...

Descripción completa

Detalles Bibliográficos
Autores principales:	Casadei-Gardini, Andrea, Scarpi, Emanuela, Ulivi, Paola, Palladino, Maria Angela, Accettura, Caterina, Bernardini, Ilaria, Spallanzani, Andrea, Gelsomino, Fabio, Corbelli, Jody, Marisi, Giorgia, Ruscelli, Silvia, Valgiusti, Martina, Frassineti, Giovanni Luca, Passardi, Alessandro
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2019
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6522652/ https://www.ncbi.nlm.nih.gov/pubmed/31191000 http://dx.doi.org/10.2147/CMAR.S198651

Ejemplares similares

Prognostic role of a new index (multi inflammatory index) in patients with metastatic colorectal cancer: results from the randomized ITACa trial
por: Casadei Gardini, Andrea, et al.
Publicado: (2020)

Prognostic role of aspartate aminotransferase-lymphocyte ratio index in patients with metastatic colorectal cancer: results from the randomized ITACa trial
por: Casadei Gardini, Andrea, et al.
Publicado: (2018)

Impact of second-line cetuximab-containing therapy in patients with KRAS wild-type metastatic colorectal cancer: results from the ITACa randomized clinical trial
por: Passardi, Alessandro, et al.
Publicado: (2017)

Right- vs. Left-Sided Metastatic Colorectal Cancer: Differences in Tumor Biology and Bevacizumab Efficacy
por: Ulivi, Paola, et al.
Publicado: (2017)

Prognostic role of serum concentrations of high-sensitivity C-reactive protein in patients with metastatic colorectal cancer: results from the ITACa trial
por: Gardini, Andrea Casadei, et al.
Publicado: (2016)

Effectiveness of bevacizumab in first- and second-line treatment for metastatic colorectal cancer: ITACa randomized trial
por: Petracci, Elisabetta, et al.
Publicado: (2020)

IL-8 and thrombospondin-1 as prognostic markers in patients with metastatic colorectal cancer receiving bevacizumab
por: Marisi, Giorgia, et al.
Publicado: (2018)

Circulating VEGF and eNOS variations as predictors of outcome in metastatic colorectal cancer patients receiving bevacizumab
por: Marisi, Giorgia, et al.
Publicado: (2017)

Prognostic Role of a New Inflammatory Index with Neutrophil-to-Lymphocyte Ratio and Lactate Dehydrogenase (CII: Colon Inflammatory Index) in Patients with Metastatic Colorectal Cancer: Results from the Randomized Italian Trial in Advanced Colorectal Cancer (ITACa) Study [Corrigendum]
Publicado: (2020)

Circulating Plasma Levels of miR-20b, miR-29b and miR-155 as Predictors of Bevacizumab Efficacy in Patients with Metastatic Colorectal Cancer
por: Ulivi, Paola, et al.
Publicado: (2018)

Inflammatory indexes as predictors of prognosis and bevacizumab efficacy in patients with metastatic colorectal cancer
por: Passardi, Alessandro, et al.
Publicado: (2016)

Radiofrequency ablation of hepatocellular carcinoma: a meta-analysis of overall survival and recurrence-free survival
por: Gardini, Andrea Casadei, et al.
Publicado: (2018)

Predictive role of multiple gene alterations in response to cetuximab in metastatic colorectal cancer: A single center study
por: Ulivi, Paola, et al.
Publicado: (2012)

Prolonged Pemetrexed Infusion Plus Gemcitabine in Refractory Metastatic Colorectal Cancer: Preclinical Rationale and Phase II Study Results
por: Passardi, Alessandro, et al.
Publicado: (2017)

Metastatic Colorectal Cancer
por: Passardi, Alessandro, et al.
Publicado: (2021)

Impact of Pre-Treatment Lactate Dehydrogenase Levels on Prognosis and Bevacizumab Efficacy in Patients with Metastatic Colorectal Cancer
por: Passardi, Alessandro, et al.
Publicado: (2015)

Molecular and Translational Research on Colorectal Cancer
por: Passardi, Alessandro, et al.
Publicado: (2020)

Relationship between hypoxia and response to antiangiogenic therapy in metastatic colorectal cancer
por: Ulivi, Paola, et al.
Publicado: (2016)

BRAF-Mutated Colorectal Cancer: Clinical and Molecular Insights
por: Caputo, Francesco, et al.
Publicado: (2019)

Immune Checkpoints as a Target for Colorectal Cancer Treatment
por: Passardi, Alessandro, et al.
Publicado: (2017)

Special Issue on Basic and Translational Research in Colorectal Cancer
por: Ulivi, Paola, et al.
Publicado: (2019)

EGFR methylation and outcome of patients with advanced colorectal cancer treated with cetuximab
por: CHIADINI, ELISA, et al.
Publicado: (2015)

Special Issue on Molecular and Translational Research on Colorectal Cancer 2.0
por: Passardi, Alessandro, et al.
Publicado: (2021)

Instability of Non-Standard Microsatellites in Relation to Prognosis in Metastatic Colorectal Cancer Patients
por: Pirini, Francesca, et al.
Publicado: (2020)

eNOS polymorphisms as predictors of efficacy of bevacizumab-based chemotherapy in metastatic colorectal cancer: data from a randomized clinical trial
por: Ulivi, Paola, et al.
Publicado: (2015)

No evidence of NRAS mutation in squamous cell anal carcinoma (SCAC)
por: Capelli, Laura, et al.
Publicado: (2016)

eNOS polymorphisms and clinical outcome in advanced HCC patients receiving sorafenib: final results of the ePHAS study
por: Gardini, Andrea Casadei, et al.
Publicado: (2016)

Itaca /
por: Aguirre, Francisca, 1930-
Publicado: (1972)

Chemoradiotherapy (Gemox Plus Helical Tomotherapy) for Unresectable Locally Advanced Pancreatic Cancer: A Phase II Study
por: Passardi, Alessandro, et al.
Publicado: (2019)

Erratum: Passardi, A. et al. Chemoradiotherapy (Gemox Plus Helical Tomotherapy) for Unresectable Locally Advanced Pancreatic Cancer: A Phase II Study. Cancers 2019, 11, 663
por: Passardi, Alessandro, et al.
Publicado: (2020)

Heterogeneity of Response and Immune System Activity during Treatment with Nivolumab in Hepatocellular Carcinoma: Results from a Single-Institution Retrospective Analysis
por: Rapposelli, Ilario Giovanni, et al.
Publicado: (2021)

KRAS, BRAF and PIK3CA Status in Squamous Cell Anal Carcinoma (SCAC)
por: Casadei Gardini, Andrea, et al.
Publicado: (2014)

Heterogeneity in Colorectal Cancer: A Challenge for Personalized Medicine?
por: Molinari, Chiara, et al.
Publicado: (2018)

Ten years of sorafenib in hepatocellular carcinoma: Are there any predictive and/or prognostic markers?
por: Marisi, Giorgia, et al.
Publicado: (2018)

Case Report: The Added Value of Liquid Biopsy in Advanced Colorectal Cancer From Clinical Case Experiences
por: Ulivi, Paola, et al.
Publicado: (2021)

Immune inflammation indicators and implication for immune modulation strategies in advanced hepatocellular carcinoma patients receiving sorafenib
por: Gardini, Andrea Casadei, et al.
Publicado: (2016)

Early onset of hypertension and serum electrolyte changes as potential predictive factors of activity in advanced HCC patients treated with sorafenib: results from a retrospective analysis of the HCC-AVR group
por: Gardini, Andrea Casadei, et al.
Publicado: (2016)

Itaca e Oltre/
por: Magris, Claudio

Paraneoplastic lipase and amylase production in a patient with small-cell lung cancer: case report
por: Casadei Gardini, Andrea, et al.
Publicado: (2016)

De Troya a Itaca
por: Ojeda, Jorge Arturo, 1943-
Publicado: (1982)

Cannot write session to /tmp/vufind_sessions/sess_kdk9jcrq2d21smq6b6jrl135r1